No Data
No Data
Sinopharm Hyundai (600420): The reform of the central enterprise chemical platform integrating API formulations is expected to improve efficiency and profitability
Sinopharm Hyundai is a chemical industry platform under the Sinopharm Group. After years of development and integration, it has formed a powerful chemical platform industrial enterprise with integrated intermediate API formulations. We believe that there is room to improve the company's current profit level and improve quality with the help of central enterprises
Sinopharm Hyundai (600420.SH): The company's current hypoglycemic drugs include engagliflozin tablets
Gelonghui, April 24 | Sinopharm Hyundai (600420.SH) said on the investor interactive platform that the company currently has glucose-lowering drugs such as engliflozin tablets, as well as the active ingredients acarbose and voglibose. None of the above drugs currently have any weight-loss-related indications.
Sinopharm Hyundai (600420.SH): Injectable ceftriaxone passes consistent evaluation of generic drug quality and efficacy
Sinopharm Hyundai (600420.SH) issued an announcement. Recently, Sinopharm Group Weiqida Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company...
Shyndec Pharmaceutical's Unit Gets Nod to Market Empagliflozin Tablets
Shanghai Shyndec Pharmaceutical's (SHA:600420) unit, Sinopharm Rongsheng Pharmaceutical, received a drug registration certificate from China's National Medical Products Administration for its empaglif
Sinopharm Hyundai (600420.SH): Empagliflozin tablets obtained drug registration certificate
Gelonghui, April 15 | Sinopharm Hyundai (600420.SH) announced that its wholly-owned subsidiary Sinopharm Group Rongsheng Pharmaceutical Co., Ltd. has received the “Drug Registration Certificate” for englizine tablets approved and issued by the State Drug Administration. Empagliflozin reduces the ability of the kidneys to recycle glucose back into the bloodstream and excretes sugar from the body through urine, which helps reduce patients' blood sugar levels.
Express News | Sinopharm Hyundai: Net profit increased 78.55% to 89.71% in the first quarter of 2024
No Data